Following the transfer of the pan-Canadian Oncology Drug Review (pCODR) to CADTH beginning in April 2014, a survey was conducted to identify stakeholder concerns regarding the transfer.
Stakeholder Information Sessions on the transfer held on June 9, 2014 were attended by patient advocacy groups, oncology professionals, pharmaceutical manufacturers, associations, and consultants. The summary report outlines the key points, questions, and comments from these sessions.
CADTH/pCODR has proposed some next steps as a result of these sessions:
- Confirm how future consultation will take place, based on this stakeholder input.
- Identify mechanisms for stakeholder engagement such as working groups.
- Hold a similar information session on the CADTH Common Drug Review program
For further information regarding the transition of pCODR to CADTH, please refer to the Summary Report